Single dose v two-dose antenatal anti-D prophylaxis: a randomised controlled trial.
CONCLUSIONS: The two-dose RAADP schedule currently recommended in Australia provides better protection against Rh(D) sensitisation than a one-dose regimen.
TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry (ACTRN12613000661774).
PMID: 31304600 [PubMed - as supplied by publisher]
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
More News: Australia Health | Babies | Clinical Trials | General Medicine | New Zealand Health | OBGYN | Pregnancy | Women